Clinical trial programme  

As an innovative pharmaceutical company, Boehringer Ingelheim has a large and experienced global team managing and conducting clinical trials in many indications. We are committed to the safety of patients who take part in our clinical trials and holding the highest standards in all of our research initiatives. Such trials are conducted to establish the potential of drugs under investigation to progress to becoming new medicines. They are fundamental to developing novel treatments of therapeutic benefit.

Our trials are conducted according to agreed international standards and in compliance with all respective regulations.

In the past decade, Boehringer Ingelheim conducted or sponsored 1,223 studies with 125 substances including approximately 1.2 million patients in study centers located in 58 countries all over the world.

Our main clinical trials are ongoing for prevention of    

• Cardiovascular diseases
• Respiratory diseases
• Cerebrovascular diseases
• Metabolic disease including diabetes.
• Oncology

Landmark trials  

Landmark trials are large-scale, randomized, controlled clinical trials with thousands of patients recruited from a great number of sites around the world. Results have potential to broadly impact on clinical practice.

Landmark studies aim to  

• Save the lives of, and create more active lives for, patients with cardiovascular, cerebrovascular and respiratory disease, which currently claim the lives of over 20 million people each year.
• Improve medical knowledge and management of stroke, heart disease and chronic obstructive pulmonary disease (COPD). By 2020 stroke, heart disease and COPD will be the three leading causes of death.
• Provide optimum care and protection for a wide range of patients, including difficult-to-treat patients and diverse ethnic populations.

Keep people active, reducing hospitalizations and the burden of healthcare costs.